PATENT CLAIM ANALYSIS

Application Number: 15877067
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "094000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 12):
The method of  claim 11 , wherein the zoledronic acid in the dosage form has a mean bioavailability of 1.6% to 2%, as determined when orally administered to a human being who: 1) has fasted for at least one hour prior to administration of the dosage form, and 2) has fasted for at least one hour after administration of the dosage form.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15604394', '15697267', '15403073', '15439774', '15702616']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8472413724656623
- 35 USC 102 Novelty (BERT): 0.6077343780387316
- Combined Prediction Score: 0.8232906730229692
- Mean Citation Score: 610.9941
- Max Citation Score: 615.6008
- Similarity Product: 496.2277758786679

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test